Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Continued obefazimod treatment led to Week 44 clinical and endoscopic responses in a substantial proportion of induction non-responders with moderately to severely active

, including 37.2% achieving clinical remission and 34.5% achieving endoscopic remission on the 50 mg dose.

ABTECT Maintenance Part 2 is the supplemental portion of the Phase 3 maintenance program evaluating obefazimod, an investigational oral miR-124 enhancer, in adults with moderately to severely active ulcerative colitis. The analysis included patients who did not achieve clinical response after an 8-week induction period and were subsequently maintained on continued therapy through Week 44.

“The robust efficacy results observed in both induction responders (Part 1) and induction non-responders (Part 2) demonstrate a consistent treatment effect across clinically important patient populations,” Remo Pannacione, MD, Professor of Medicine and Director of the IBD Clinic at the University of Calgary said in a press release.

Among induction non-responders who continued treatment, obefazimod was associated with consistent improvements across multiple endpoints at Week 44, including clinical response (61.5%), endoscopic improvement (48.0%), and histologic-endoscopic mucosal improvement (44.6%), in addition to clinical remission (37.2%) and endoscopic remission (34.5%).

These findings suggest that lack of early response does not preclude later clinical or endoscopic benefit, reinforcing the potential for delayed treatment response with continued exposure to obefazimod.

Dose escalation associated with response recapture after relapse

In a separate exploratory analysis, dose escalation to 50 mg obefazimod was associated with recapture of clinical and endoscopic outcomes in patients who relapsed during Maintenance Part 1.

Patients who initially responded during induction but relapsed after switching to placebo achieved clinical response and remission rates of 69.7% and 45.0%, respectively, following re-treatment with 50 mg. Those who relapsed on 25 mg and escalated to 50 mg achieved clinical response and remission rates of 66.7% and 45.5%, respectively, suggesting potential for re-establishing disease control following loss of response during maintenance therapy.

Safety consistent with prior experience across integrated program

Across the integrated Phase 2 and Phase 3 ulcerative colitis program, which includes 1,704 patient-years of exposure, exposure-adjusted incidence rates for malignancies excluding non-melanoma skin cancer remained consistent with expected background rates in ulcerative colitis populations. Rates of non-melanoma skin cancer were also generally consistent with published epidemiologic benchmarks, with no new safety signals identified.

Findings from ABTECT Maintenance Part 2 were consistent with the broader program, including the Phase 3 maintenance dataset, and did not reveal any new safety concerns with increased cumulative exposure.

Clinical perspective: delayed response and flexible maintenance exposure

Taken together, the ABTECT Maintenance Part 2 results suggest that early non-response to obefazimod does not necessarily predict lack of later benefit, with clinically meaningful responses observed through Week 44 in a substantial proportion of patients. The data also indicate that disease control may be re-established following relapse with dose escalation, supporting a flexible maintenance approach in a heterogeneous ulcerative colitis population.

Overall, the findings expand the evidence base for obefazimod in ulcerative colitis by demonstrating late and recaptured responses in patients with refractory disease, while maintaining a safety profile consistent with expected background rates. These results support continued evaluation of obefazimod as a potential long-term therapeutic option across a broad spectrum of patients with ulcerative colitis.

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database. Abivax. Published June 30, 2026. Accessed June 30, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1. Clinical Trials. Published 2025. Accessed June 30, 2026. 

https://clinicaltrials.gov/study/NCT05507203

Articles

Continued obefazimod exposure through Week 44 produced clinically meaningful delayed responses in adults with moderately to severely active ulcerative colitis who failed to respond after 8-week induction. In induction non-responders maintained on therapy, Week 44 outcomes included clinical response 61.5%, clinical remission 37.2%, endoscopic improvement 48.0%, endoscopic remission 34.5%, and histologic-endoscopic mucosal improvement 44.6% on 50 mg. Exploratory data suggested relapse during maintenance could be mitigated by dose escalation to 50 mg, with safety consistent with background ulcerative colitis rates.

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Saakshi Khattri, MD, discusses how real-world comparative effectiveness data suggest a potential class-level signal for risankizumab and IL-23 inhibition in reducing the risk of psoriatic arthritis among patients with psoriasis.

Real-World Data on Risankizumab and Psoriatic Arthritis Prevention in Psoriasis

In this discussion, Saakshi Khattri, MD, a rheumatologist and dermatologist at the Icahn School of Medicine at Mount Sinai, reviews emerging real-world evidence on risankizumab in psoriatic disease, with a focus on psoriatic arthritis (PsA) prevention. She notes that for clinicians managing patients with psoriasis, the possibility of reducing PsA risk is a central concern, yet prospective prevention trials directly comparing mechanisms of action (MOAs) are lacking. In this context, real-world comparative effectiveness data have become an important—albeit imperfect—source of insight.

Khattri explains that analyses of real-world datasets suggest patients with psoriasis treated with risankizumab are less likely to develop PsA than those receiving other targeted immunomodulators. She emphasizes that these findings are based on observational claims and registry data, not on prospective prevention trials, and therefore must be interpreted cautiously.

Nonetheless, in the absence of randomized data, she considers “any data better than no data,” particularly when it consistently signals a lower incidence of PsA in association with IL-23 inhibition.

From a mechanistic standpoint, Khattri points out that IL-23 is a key upstream cytokine implicated in both cutaneous and joint inflammation in psoriatic disease. Blocking IL-23 may therefore be biologically plausible as a strategy to blunt progression from skin-only psoriasis to PsA.

While she underscores that these findings do not establish proof of prevention, she reports that this emerging signal influences her systemic therapy selection for patients who currently have psoriasis alone but are at risk for future PsA.

Videos

Video Series

2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD

 guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other organizations, have redefined lipid management as a more unified and aggressive prevention-focused strategy across all ages.

Roger Blumenthal, MD, director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and Kenneth Jay Pollin Professor of Cardiology at Johns Hopkins Medicine, discussed the updated guidelines for both the US and Europe at the 

“Essentially, we made it much easier for clinicians and patients to justify making an effort to comprehensively improve dietary and exercise habits,” Blumenthal told 

 in an exclusive interview. “But, after a period of time, if they can’t reach their lipid goals, then we make it easier to qualify for the use of medication to get to those targets.”

The ACC/AHA guidelines, published in March 2026, reemphasized the importance of early intervention in dyslipidemia. By implementing health behavior counseling in youth, clinicians can significantly reduce a patient’s likelihood of cardiovascular disease down the line. Specifically, the document suggests that clinicians consider pharmacotherapy in adolescents with familial hypercholesterolemia (FH) and young adult patients with LDL-C ≥160 mg/dL, as well as those with a strong family history of premature 

atherosclerotic cardiovascular disease (ASCVD)

Additionally, the guidelines highlighted the PREVENT equations, reestablishing them after years of suggesting the less specific Pooled Cohort Equations (PCE). The PCE were derived from roughly 25,000 patients, with some from older birth cohorts; the PREVENT equations, meanwhile, were developed from >3,000,000 individual patients from both population-based and clinical datasets. The significantly greater specificity of the PREVENT equations motivated the shift back after years of promoting PCE.

Another key factor in the updated guidelines is the increased focus on LDL-C-lowering therapy, with LDL-C and non-HDL-C treatment goals once more at the forefront of lipid-lowering therapy. Prior to the release of this document, percentage reduction in LDL-C was the cornerstone of lipid-lowering therapy – while it still remains a priority, it is once again in a back seat to the more specific and informative LDL-C goals measurement.

The guidelines also substantially support the measurement of lipoprotein(a) and apolipoprotein B (ApoB) to determine ASCVD risk and to guide therapy following the achievement of LDL-C goals, respectively. Lipoprotein(a) is considered a risk-enhancing factor in many patients, and its elevation should warrant more intensified lowering of LDL-C. Additionally, ApoB serves as a secondary marker to prevent missing adult patients with residual elevated lipoprotein-related risk that could be underrepresented by standard lipid profiles.

“If a patient knows that they’re at much higher risk, they’re going to change their priorities. They’re going to make time to exercise three or four times a week, rather than once a week,” Blumenthal said. “They’ll really put the emphasis on eating more fruits and vegetables, seafood, less of the sweets and fried foods. Knowledge is power, and if we can motivate people, that will be the secret to lowering their long-term risk of heart attack and stroke.”

Editors’ Note: Blumenthal reports no relevant disclosures.

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17). 

Abuhalimeh B, Alhmouz M, Behrooz L, et al. Implications of the 2026 ACC/AHA/Multiscoeity Dyslipidemia Guideline for Lipid Management in Vascular Disease. 

. June 16, 2026. Accessed June 30, 2026. 

https://www.acc.org/latest-in-cardiology/articles/2026/06/15/14/16/implications-of-the-2026-multisociety-dyslipidemia-guideline

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care, With Gideon Hirschfield, FRCP, PhD

Miriam Pharmaceuticals presented late-breaking, full results from VISTAS, a phase 2b study evaluating volixibat in patients with 

, at the European Association for the Study of the Liver (EASL) meeting, with plans to submit a new drug application (NDA) to the 

by the second half of summer 2026. If approved, volixibat would be the first FDA-approved therapy specifically targeting cholestatic pruritus in PSC.

Volixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, was associated with statistically significant and rapid improvements in pruritus, with separation from placebo observed within 2 weeks. In the primary endpoint, patients receiving volixibat achieved a 2.72-point reduction in pruritus versus baseline and a placebo-adjusted difference of 1.64 points (P <.0001), as measured by the Adult ItchRO scale.

 spoke with Gideon Hirschfield, FRCP, PhD, Director of the Autoimmune and Rare Liver Disease Programme, to discuss the data and its implications for patient-centered care in PSC, particularly around symptom burden related to itch and fatigue.

“If I told you that you have a headache and I'm going to give you Tylenol, but you have to wait a month for the Tylenol to work, you're not going to take it,” Hirschfield said. “It's exactly the same if I tell a patient who's got cholestatic pruritus due to PSC that I have a treatment that, within 1 to 2 weeks, they'll be able to tell immediately that it's helping them. That's patient-centered care.”

Pruritus is one of the most common and burdensome symptoms of PSC and is strongly associated with impaired sleep and reduced quality of life. The primary endpoint assessed change in the Adult ItchRO scale, a validated 0–10 numerical rating scale in which 0 indicates no itch and 10 indicates worst itch imaginable.

The VISTAS trial enrolled 158 patients with PSC, assigned to a primary analysis cohort (moderate-to-severe itch; n = 111) or a secondary cohort (mild itch; n = 47) based on baseline severity. Patients were randomized to volixibat 20 mg twice daily or placebo.

A ≥2-point reduction in itch was achieved in 56% of patients receiving volixibat versus 26% with placebo (

 = .0019), while a ≥3-point reduction was seen in 37% versus 11%, respectively (P = .0011).

These improvements were accompanied by reductions in serum bile acids (sBA), with a mean decrease of 33.7 µmol/L compared with a 2.1 µmol/L increase in placebo, for a placebo-adjusted difference of −35.8 µmol/L (

 = .0324). Mechanistically, IBAT inhibition reduces enterohepatic circulation of bile acids, lowering systemic exposure. Bile acid accumulation is thought to contribute to cholestatic pruritus via activation of sensory pathways including MRGPRX4 and TGR5, which transmit itch signaling to the central nervous system.

Fatigue affects an estimated 70% to 75% of patients with PSC and is often independent of biochemical disease activity, reflecting its multifactorial pathophysiology.

“We do expect that when you improve itch, you would also have an improvement in sleep disturbance related to pruritus, and I think that’s what we see,” Hirschfield said. “We’d like to see whether or not that then translates into other symptom improvements, but at this stage it’s quite early days in terms of those analyses. Fatigue is a very complex symptom and there isn’t a complete immediate overlap between fatigue and pruritus, so it’s quite possible that drugs that improve pruritus and sleep disturbance may not directly have a quantifiable improvement in fatigue.”

Investigators reported improvements in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep scores (placebo-adjusted difference −5.69;

= .0011) and numerical trends in fatigue scores (−2.33; 

Volixibat’s safety profile was consistent with IBAT inhibition, with gastrointestinal adverse events and laboratory changes including increases in ALT, AST, ALP, and bilirubin observed versus placebo. These findings were not reported as dose-limiting but will require continued evaluation in longer-term studies.

Editors’ note: Hirschfield reports relevant disclosures with CymaBay, Ipsen, Gilead, Intercept, Mirum, Kowa, GSK, Pliant Therapeutics, and Escient.

Levy C, Hirschfield GM, Shiffman ML, et al. Efficacy and safety of volixibat, an IBAT inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the VISTAS trial. 

 2026;84(Suppl 1):S10-S11. doi:10.1016/S0168-8278(26)00310-7.

Mirum Pharmaceuticals, Inc. Volixibat demonstrates statistically significant improvement in pruritus in patients with primary sclerosing cholangitis in the VISTAS phase 2b study. News release. May 4, 2026. Accessed June 30, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-VISTAS-Study-of-Volixibat-in-Patients-with-Primary-Sclerosing-Cholangitis/default.asp

Gideon Hirschfield, FRCP, PhD, discusses phase 2b results from VISTAs, evaluating volixibat in PSC


Hepatology

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care

Rajani Katta, MD, clinical professor of dermatology at McGovern Medical School, University of Texas

Diet and Dermatology: What to Say When Your Patients Ask

As social media continues to shape patient perceptions of health, dermatology clinicians are fielding more questions than ever about the role of diet in 

 Society of Dermatology Physician Assistants (SDPA) 2026 Annual Meeting

, Rajani Katta, MD, clinical professor of dermatology at McGovern Medical School, University of Texas, addressed how clinicians can respond to those questions with confidence and nuance.

"Our patients are constantly asking about it," Katta told 

. "With influencers and a lot of social media, patients have a lot of questions about [whether they] need to be changing their diet for their skin condition. I wanted to equip clinicians with evidence-based information they can actually explain to their patients."

Her talk opened by dismantling 2 opposing myths that she says bracket most patient misconceptions. Myth 1: Diet has no relationship to dermatology. Myth 2: Diet is the cause of all dermatology problems. Navigating between those extremes, she argued, is where the real clinical work lives.

That tension is particularly evident in conditions like psoriasis and atopic dermatitis. Parents of children with eczema often arrive convinced that diet is the primary driver, while patients with psoriasis may blame themselves for poor eating habits. Katta cautioned against both overcorrection and dismissal, framing dietary intervention as a potential adjunct rather than a root cause or cure.

Her session reviewed evidence across 8 skin conditions, including rosacea, acne, chronic urticaria, and psoriasis. In acne, she highlighted research linking high-glycemic diets to worsening disease, as well as specific supplements that can serve as triggers. Whey protein supplements, certain muscle-building products adulterated with undisclosed anabolic steroids, and high-dose vitamin B6 and B12 supplements were among those flagged. Iodine supplements also made the list.

"In the past I would never have asked a patient with acne, are you taking any supplements," she said. "But as supplements have become way more popular, it's really important to ask all our patients this."

For psoriasis, the discussion shifted toward comorbidity management. Patients with psoriasis carry elevated risk for obesity, diabetes, hypertension, and dyslipidemia, and Katta emphasized that dietary counseling in this population should address systemic risk alongside skin disease. She noted that emerging data on anti-inflammatory Mediterranean dietary patterns showed early promise for improving psoriasis itself, though she described the current research base as limited.

She also pointed to growing interest in GLP-1 receptor agonists, which may benefit psoriasis severity indirectly through weight loss.

Her core clinical pearl was a call for ownership. Rather than redirecting patients to nutritionists or primary care providers, she urged dermatology clinicians to learn the fundamentals and integrate dietary counseling into their own practice.

"I want us to be able to take ownership and learn the basics," she said, "so that you can either educate a patient on the triggers or potential helpers for their skin disease or refer to a provider who can."

Katta R. Integrative Medicine Track: Diet and Dermatology: What To Say When Your Patients Ask. Session presented at the 2026 SDPA Summer Dermatology Conference in Denver, Colorado, from June 10 – 14.

Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, et al. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. 

. 2025;161(12):1215-1223. doi:10.1001/jamadermatol.2025.3410

Haran K, Johnson CE, Smith P, et al. Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review. 

. 2024;14:143-152. Published 2024 Nov 15. doi:10.2147/PTT.S485061

Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA News

FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis

In, ‘Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk’, panelists will continue their discussion on hypercortisolism and highlight how cortisol excess can contribute to hypertension and cardiovascular risk even in the absence of classic Cushing syndrome features. They also explore emerging evidence linking hypercortisolism to adverse cardiometabolic outcomes and the implications for cardiovascular practice.

Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk

Aboul-Fettouh outlines his follow-up schedule for patients on JAK inhibitors, explains why he defers any meaningful hair-regrowth conversation until at least 6 months into therapy, and reflects on the reward of guiding patients through a treatment journey that was unavailable to them just a few years ago.

Monitoring Response and Setting Expectations: A Long-Term Partnership With Patients

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover recent data released by Eledon regarding tegoprubart for type 1 diabetes.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Functional Cures for T1D: Insulin Independence Through Islet Transplantation

In this episode, ‘The Challenge of Resistant Hypertension,’ features the panelists discussing persistent barriers to blood pressure control, evolving hypertension management strategies, and the importance of recognizing secondary causes of resistant hypertension. They also explore how missed opportunities for diagnosis may contribute to ongoing cardiovascular risk in clinical practice.

The Challenge of Resistant Hypertension

Aboul-Fettouh outlines the documentation strategies, appeal pathways, and manufacturer resources that dermatology practices can leverage to overcome payer barriers and get patients with alopecia areata onto the systemic therapies they need.

Navigating Insurance Barriers: Prior Authorizations, Appeals, and Manufacturer Support

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

FDA approves steroid-free roflumilast cream for plaque psoriasis in children age 2+, bringing once-daily option for sensitive areas.

FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has approved veligrotug-vvze for thyroid eye disease regardless of activity or duration.

Thyroid Disorders

FDA Approves Veligrotug-vvze for Thyroid Eye Disease

Hüseyin Demirbilek is a pediatric endocrinologist at Hacettepe University Faculty of Medicine in Ankara, Turkey.

Ersodetug showed target engagement and hypoglycemia reduction trends in phase 3 cHI study but missed primary endpoints in SunRIZE trial.

Ersodetug Shows Target Engagement but Misses Primary Endpoints in Phase 3 cHI Study

Allergy PA at Arizona Asthma and Allergy Institute

Heather O'Connell, PA-C, an allergy and asthma PA, describes how she uses clinical research and structured follow-up to shift patient thinking about the nose-lung connection, and why APPs bring a distinct advantage to that conversation.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Latest News

Obefazimod Delivers Week 44 Remission in Refractory UC Patients

Real-World Data on Risankizumab and Psoriatic Arthritis Prevention in Psoriasis

2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care

Diet and Dermatology: What to Say When Your Patients Ask